Drug intelligence / Profile preview

CD33-CAR-T cell infusion

Development stage: Unknown
Lead developer: Precigen
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD33-CAR-T cell infusion is a type of Chimeric Antigen Receptor T-cell (CAR-T cell) therapy developed by Precigen. It is designed to treat acute myeloid leukemia (AML) by targeting the CD33 antigen on cancer cells. The therapy involves engineering a patient's T-cells to express a chimeric antigen receptor that specifically recognizes and binds to CD33, leading to the destruction of CD33-expressing leukemia cells.

Other names: Anti-CD33 CAR T CellsAnti-CD-33 CAR T CellsAnti-CD 33 CAR T CellsAnti-CD33 CAR-T CellsAnti-CD-33 CAR-T CellsAnti-CD 33 CAR-T CellsCD33-CAR T CellsCD-33-CAR T CellsCD 33-CAR T CellsCART-33CART33CART 33

Targets

SIGLEC6 (Siglec-6)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on CD33-CAR-T cell infusion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD33-CAR-T cell infusion.

Explore the full profile